Key facts
- It has raised $134.0M; the latest was Early Stage VC ($89.0M) in Mar 2026.
- Notable investors include RA Capital Management, Qiming Venture Partners, OrbiMed, Foresite Capital, Logos Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Pinnacle Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Pinnacle Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pinnacle Medicines
Operator of a peptide drug discovery company intended to transform patients' lives through oral peptide therapeutics. The company utilizes artificial intelligence-based drug design tools for research, offering medical companies safe, effective, and convenient therapeutics to address unmet medical needs.
- Sector
- Healthcare
- HQ
- Doylestown, PA, United States
- Founded
- 2024
- Employees
- 18
- Website
- pinnaclemedicines.com/
- Ownership
- Privately Held (backing)
Pinnacle Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pinnacle Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pinnacle Medicines in its N-PORT filings yet. We sweep new filings monthly.